Bayer to seek approval for haemophilia drug this month

December 2, 2014 10:44 AM

10 0

Bayer to seek approval for haemophilia drug this month

FRANKFURT (Reuters) - Drugmaker Bayer AG said on Tuesday it will this month file for approval of its experimental haemophilia drug Bay 81-8973, based on its established Kogenate brand, as it seeks to build a range of treatments against the hereditary bleeding disorder.

The German company in March unveiled plans to spend more than 500 million euros ($622 million) to set up haemophilia drug production sites in Germany, in a sign of confidence in its development pipeline.

Also read: FDA approves first 2-drug HIV regimen

Read more

To category page

Loading...